Merck (MRK) Risk Assessment

View and export this data going back to 1949. Start your Free Trial

What is Merck Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Merck is: Low Risk: Strong fundamentals, worth long-term holding.

Competitive Comparison of Merck's Risk Assessment

For the Drug Manufacturers - General subindustry, Merck's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merck's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Merck's Risk Assessment falls into.

Merck (NYSE:MRK) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Merck Risk Assessment Related Terms

Thank you for viewing the detailed overview of Merck's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck (MRK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

MRK:Peru MRK:Mexico 1MRKX:Italy 6MKd:UK 0QAH:UK 6MK:Germany 6MK:Germany 6MK:Germany 6MK:Germany MRK:Chile MRCK34:Brazil MRK:Austria MRK:Argentina

Address

126 East Lincoln Avenue, Rahway, NJ, USA, 07065

Website

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Executives

Johannes Jacobus Oosthuizen	officer: SVP, U.S. Market	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Richard R. Deluca	officer: EVP&Pres, Merck Animal Heallth	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steven Mizell	officer: EVP,Human Resources	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Joseph Romanelli	officer: President, Human Health Int?l	126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Rita A Karachun	officer: Sr. VP Fince-Global Controller	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jennifer Zachary	officer: EVP, General Counsel	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams	officer: EVP,Chief Info&Digital Officer	MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Robert M Davis	officer: Evp, Global Svcs & CFO	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Sanat Chattopadhyay	officer: Exe V-P & Pres. MMD	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kenneth C Frazier	officer: Chairman, President & CEO	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Chirfi Guindo	officer: Chief Marketing Officer	C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr	director	370 WBASHA ST NORTH, ST PAUL MN 55102
Arpa Garay	officer: SVP Human Health Global Mktg.	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield	officer: EVP & CFO	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Julie L. Gerberding	officer: EVP Strat Comm, GI Pub Policy	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033